Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pembrolizumab versus chemotherapy in mismatch repair-deficient advanced or recurrent endometrial cancer; the study is active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING